Related references
Note: Only part of the references are listed.Validation of a Next-Generation Sequencing Assay for Clinical Molecular Oncology
Catherine E. Cottrell et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
Technical and implementation issues in using next-generation sequencing of cancers in clinical practice
D. Ulahannan et al.
BRITISH JOURNAL OF CANCER (2013)
Oncogenic Mutations in Cervical Cancer Genomic Differences Between Adenocarcinomas and Squamous Cell Carcinomas of the Cervix
Alexi A. Wright et al.
CANCER (2013)
Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: A systematic review
Maria Lina Tornesello et al.
GYNECOLOGIC ONCOLOGY (2013)
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma
Diego A. Garcia-Dios et al.
GYNECOLOGIC ONCOLOGY (2013)
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy
John B. McIntyre et al.
GYNECOLOGIC ONCOLOGY (2013)
Lessons learned from next-generation sequencing in head and neck cancer
Myriam Loyo et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers
Isaac Kinde et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
Libero Santarpia et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer
Han Liang et al.
GENOME RESEARCH (2012)
Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation
Remi A. Nout et al.
GYNECOLOGIC ONCOLOGY (2012)
Racial Differences in Oncogene Mutations Detected in Early-Stage Low-Grade Endometrial Cancers
Michele L. Cote et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma
Ken Dutton-Regester et al.
MOLECULAR CANCER THERAPEUTICS (2012)
PPP2R1A mutations are common in the serous type of endometrial cancer
Deepak C. Nagendra et al.
MOLECULAR CARCINOGENESIS (2012)
High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations
Chi Hoon Maeng et al.
PLOS ONE (2012)
High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated
Camilla Krakstad et al.
PLOS ONE (2012)
Somatic Mutations of PPP2R1A in Ovarian and Uterine Carcinomas
Ie-Ming Shih et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Genetic Alterations in the K-Ras Gene Influence the Prognosis in Patients With Cervical Cancer Treated by Radiotherapy
Pia Wegman et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Role of TP53 Mutations in Vulvar Carcinomas
Matthias Choschzick et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2011)
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas
Melissa K. McConechy et al.
JOURNAL OF PATHOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR
Ronald van Eijk et al.
PLOS ONE (2011)
A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes
Debora Fumagalli et al.
BMC CANCER (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Sian Jones et al.
SCIENCE (2010)
PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas
Chih-Ming Ho et al.
GYNECOLOGIC ONCOLOGY (2009)
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Sohrab P. Shah et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
Laura E. MacConaill et al.
PLOS ONE (2009)
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Amit Dutt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Inactivation of the CDKN2A and the p53 tumour suppressor genes in external genital carcinomas and their precursors
N. Soufir et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas et al.
NATURE GENETICS (2007)
Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer
AE de Jong et al.
CLINICAL CANCER RESEARCH (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma
ML Gemignani et al.
GYNECOLOGIC ONCOLOGY (2003)
A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas
WG McCluggage et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2002)
Share Paper
